VCM
INBX icon

Versant Capital Management’s Inhibrx INBX Stock Holding History

Versant Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Hold
168
– – ﹤0.01% 2042
2026
Q1 		$11.3K Hold
168
– – ﹤0.01% 2087
2025
Q4 		$13.3K Hold
168
– – ﹤0.01% 1873
2025
Q3 		$5.66K Hold
168
– – ﹤0.01% 2162
2025
Q2 		$2.4K Sell
168
-228
-58% -$2.95K ﹤0.01% 2345
2025
Q1 		$5.54K Buy
+396
New +$5.38K ﹤0.01% 1996

Other funds holding INBX

EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
DAS
Dynamic Advisor Solutions Phoenix, Arizona $3.53B AUM 22.61% 1-Year Est. Return
PCM
Presidio Capital Management San Diego, California $400M AUM 22.73% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Versant Capital Management's INBX Position: Q2 2026 in Review

Versant Capital Management held its Inhibrx (INBX) position steady in Q2 2026 at 168 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Versant Capital Management first reported a position in INBX in Q1 2025 and has held it in 6 quarters since. 10 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Versant Capital Management held 168 shares of Inhibrx worth $15.9K as of Q2 2026.
  • Versant Capital Management left its Inhibrx share count unchanged in Q2 2026.
  • Inhibrx made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2042 holding.
  • Versant Capital Management first reported a position in Inhibrx in Q1 2025 and has held it in 6 quarters since.
  • 10 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.